In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

In hearings around the world, politicians and experts called for inquiries into inequities surrounding Merck's anti-cancer ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...